You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 16, 2025

Drug Price Trends for BRIMONIDINE


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for BRIMONIDINE

Best Wholesale Price for BRIMONIDINE

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available to any customer under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Unit Dates Price Type
BRIMONIDINE TARTRATE 0.2% SOLN,OPH Sandoz, Inc. 61314-0143-05 5ML 1.67 0.33400 ML 2023-08-15 - 2028-08-14 FSS
BRIMONIDINE TARTRATE 0.2% SOLN,OPH Sandoz, Inc. 61314-0143-10 10ML 2.65 0.26500 ML 2023-08-15 - 2028-08-14 FSS
BRIMONIDINE TARTRATE 0.2% SOLN,OPH Sandoz, Inc. 61314-0143-15 15ML 3.27 0.21800 ML 2023-08-15 - 2028-08-14 FSS
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Unit >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for Brimonidine

Overview of Brimonidine

Brimonidine is an alpha-2 adrenergic agonist widely used in the treatment of glaucoma and ocular hypertension. It is known for its selective binding to alpha-2 adrenergic receptors, which helps in reducing intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow[4].

Market Value and Growth Projections

The glaucoma treatment market, which includes brimonidine, is projected to experience significant growth. According to GlobalData, the market value for glaucoma treatments is expected to rise from $2.4 billion in 2013 to approximately $3 billion by 2023 across seven major markets: the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan. This growth represents a moderate compound annual growth rate (CAGR) of 2.4%[1][5].

Key Drivers of Market Growth

Several factors are driving this growth:

  • Approval of Innovative Drugs: The introduction of new drugs such as Roclatan (Aerie Pharmaceuticals), latanoprostene bunod (Vesneo; Bausch + Lomb), and trabodenoson (Inotek Pharmaceuticals) will significantly impact the market. These drugs, particularly Roclatan, are expected to achieve high sales due to their innovative formulations and market positioning[1][5].
  • Fixed-Dose Combination (FDC) Products: The introduction of additional FDC products like tafluprost and timolol maleate (Santen), and brimonidine and brinzolamide (Simbrinza; Alcon) will also contribute to market growth. These combinations offer convenience and potentially better therapeutic outcomes, driving their adoption[1][5].

Role of Brimonidine in the Market

Brimonidine, particularly in its combination form with brinzolamide (Simbrinza), plays a crucial role in the glaucoma treatment market. Here are some key points:

  • Combination Therapies: Brimonidine combined with brinzolamide (Simbrinza) is a significant player in the FDC segment. This combination is effective in reducing intraocular pressure and offers a convenient dosing regimen for patients[1][5].
  • Patent Protection and Generic Entry: Allergan's FDC drug Combigan (brimonidine and timolol) will lose patent protection in 2022, allowing generic versions to enter the market. This could impact the market dynamics and pricing for brimonidine-based products[1][5].

Pricing and Cost Analysis

The pricing of brimonidine can vary based on several factors, including the concentration of the solution, the quantity purchased, and the pharmacy.

  • Current Pricing:
    • Brimonidine ophthalmic solution 0.1% can cost around $139 for a 5 milliliter supply, with prices ranging from $27.75 to $39.58 per milliliter[2].
    • The 0.15% solution can cost from $62.21 for a 5 milliliter supply, with prices ranging from $12.44 to $14.92 per milliliter[2].
    • The 0.2% solution can cost from $16.62 for a 10 milliliter supply, with prices ranging from $1.66 to $2.61 per milliliter[2].
  • Yearly Costs:
    • The yearly cost of generic brimonidine tartrate 0.2% can range from $352.89 to $529.34, depending on the dosing regimen (two or three drops daily per eye)[3].

Impact of Market Trends on Pricing

The introduction of new drugs and combination therapies, along with the loss of patent protection for existing products, can influence pricing:

  • Competition from New Drugs: The entry of new innovative drugs may lead to competitive pricing strategies, potentially reducing the prices of existing treatments like brimonidine[1][5].
  • Generic Entry: The availability of generic versions of brimonidine and timolol combinations after patent expiration in 2022 is expected to lower prices and increase market competition[1][5].

Regional Market Dynamics

The United States is expected to remain the dominant market for glaucoma treatments, including brimonidine. Here are some regional insights:

  • US Market Growth: The US market for glaucoma treatments is projected to grow from $1.7 billion in 2013 to $2.2 billion by 2023, with a CAGR of 2.5%. This growth is driven by new product introductions and an increase in glaucoma prevalence due to an aging population[1][5].

Conclusion

Brimonidine is a significant player in the glaucoma treatment market, with its use expected to continue due to its efficacy and safety profile. The market for glaucoma treatments, including brimonidine, is projected to grow moderately, driven by innovative drugs and combination therapies. However, the pricing landscape may evolve with the introduction of generics and new competitive products.

Key Takeaways

  • The glaucoma treatment market is expected to grow from $2.4 billion in 2013 to $3 billion by 2023.
  • Brimonidine, especially in combination with brinzolamide, is a key product in this market.
  • New drug approvals and the introduction of FDC products will drive market growth.
  • The loss of patent protection for existing products like Combigan will lead to generic entries, potentially affecting pricing.
  • The US market will remain dominant, driven by new product introductions and an aging population.

FAQs

What is brimonidine used for?

Brimonidine is used to treat glaucoma and ocular hypertension by reducing intraocular pressure. It is also used to treat facial erythema in rosacea[4].

How does brimonidine work?

Brimonidine works by reducing aqueous humor production and increasing uveoscleral outflow, thereby lowering intraocular pressure. It is a selective alpha-2 adrenergic agonist[4].

What are the common concentrations of brimonidine ophthalmic solution?

Common concentrations include 0.1%, 0.15%, and 0.2% solutions[2].

How much does brimonidine ophthalmic solution cost?

The cost can range from $139 for a 5 milliliter supply of 0.1% solution to $16.62 for a 10 milliliter supply of 0.2% solution, depending on the pharmacy and quantity[2].

What impact will the loss of patent protection for Combigan have on the market?

The loss of patent protection for Combigan (brimonidine and timolol) in 2022 will allow generic versions to enter the market, potentially reducing prices and increasing competition[1][5].

Sources

  1. Glaucoma Treatment Market Value Projected to Hit $3 Billion by 2023 - GlobalData, July/August 2015.
  2. Brimonidine ophthalmic Prices, Coupons, Copay Cards & Patient Assistance - Drugs.com.
  3. Cost analysis of glaucoma medications - PubMed.
  4. Brimonidine: Uses, Interactions, Mechanism of Action - DrugBank.
  5. Industry News and Innovations - Glaucoma Today, July/August 2015.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.